FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HENDERSON MICHAEL THOMAS					2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [ BBIO ]									Check	all app	o of Reportir licable) tor er (give title	ng Pei	rson(s) to Is 10% Ov Other (s	wner
(Last) (First) (Middle) C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2020									X	below)  Chief Busines			below)	specify
(Street) PALO ALTO CA 94301 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)									. Indiv ine) X	·						
		Table	1 - 1	Non-Deriva	tive	Secui	rities	Acc	quir	ed, Di	sposed o	f, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea				Execution		n Date,	ָּ   בֿ	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Sed Ber Ow		Amount of curities neficially ned Following ported		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								c	Code	v	Amount	(A) or (D)	Price		Transa	ransaction(s) Instr. 3 and 4)		u. 4)	(111501.4)
Common Stock 06/03/2020				.0				S <sup>(1)</sup>		784	D	\$30.0364(2)		261,399			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any				sunsaction de (Instr. Securitie Acquirer (A) or Dispose of (D) (Instr. 3, and 5)		ative rities ired sed	Expiration Date (Month/Day/Year)			Amor Secu Unde Deriv	rlying ative rity (Instr.   4)   Amount or	Deri Sec	rice of vative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	e ercisable	Expiration Date	Title	Number of Shares						

## **Explanation of Responses:**

- 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019.
- 2. Represents the weighted average sale price of the shares sold from \$30.00 to \$30.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

## Remarks:

/s/ Tara Condon, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person Date

06/04/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.